Johnson & Johnson will acquire Intra-Cellular Therapies for $132.00 (€126.66) per share in cash for a total equity value of approximately $14.6 billion (€14 billion).

“Building on our nearly 70-year legacy in neuroscience, this unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitment to transforming care and advancing research in some of today’s most devastating neuropsychiatric and neurodegenerative disorders,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “This acquisition further differentiates our portfolio, serves as a strategic near- and long-term growth catalyst for Johnson & Johnson and offers compelling value to patients, health systems and shareholders.”

With this agreement, Johnson & Johnson adds Intra-Cellular Therapies’ caplyta (lumateperone), an oral therapy approved to treat adults with schizophrenia and bipolar depressive episodes. The acquisition also includes a clinical-stage pipeline that further complements and strengthens Johnson & Johnson’s current areas of focus.

“We are excited to welcome Intra-Cellular Therapies’ talented people and world-class expertise to Johnson & Johnson,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “Together, we have an opportunity to impact even more patients living with neuropsychiatric and neurodegenerative disorders, significantly advancing care and helping improve the lives of millions worldwide.”

The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals and customary closing conditions.